• 1
    Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 6990
  • 2
    American Cancer Society. Global Cancer Facts & Figures, 2nd edn. Atlanta, GA: Atlanta, USA: American Cancer Society; 2011
  • 3
    Schned AR, Andrew AS, Marsit CJ et al. Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States. Scand J Urol Nephrol 2008; 42: 237242
  • 4
    Holmäng S, Hedelin H, Anderström C et al. Prospective registration of all patients in a geographical region with newly diagnosed bladder carcinomas during a two-year period. Scand J Urol Nephrol 2000; 34: 95101
  • 5
    Kiemeney LA, Witjes JA, Heijbroek RP et al. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993; 150: 6064
  • 6
    Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005; 66: 434
  • 7
    Allard P, Bernard P, Fradet Y et al. The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index. Br J Urol 1998; 81: 692698
  • 8
    Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 31A: 18401846
  • 9
    Bostwick DG. Natural history of early bladder cancer. J Cell Biochem Suppl 1992; 161: 3138
  • 10
    Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180183
  • 11
    Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 12051209
  • 12
    Morales A, Ottenhof P, Emerson L. Treatment of residual, non-infiltrating bladder cancer with bacillus Calmette-Guerin. J Urol 1981; 125: 649651
  • 13
    Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303314
  • 14
    Di Stasi SM, Giannantoni A, Giurioli A et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006; 7: 4351
  • 15
    Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2: the Cochrane Collaboration. 2009
  • 16
    Ali-El-Dein B, Nabeeh A, Ismail EH et al. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. J Urol 1999; 162: 339342
  • 17
    Cai T, Nesi G, Tinacci G et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. J Urol 2008; 180: 110115
  • 18
    Kaasinen E, Wijkström H, Malmström PU et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol 2003; 43: 637645
  • 19
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 11241129
  • 20
    Martínez-Piñeiro JA, Martínez-Piñeiro L, Solsona E et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174: 12421247